TNX 801
Alternative Names: Smallpox and monkeypox vaccines - Tonix Pharmaceuticals/University of Alberta; TNX-801Latest Information Update: 05 May 2025
At a glance
- Originator Leder Laboratories; University of Alberta
- Developer Tonix Pharmaceuticals Holding Corp
- Class Attenuated vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Monkeypox; Smallpox
Most Recent Events
- 24 Apr 2025 Adverse events and pharmacodynamics data from a preclinical study in Monkey Pox and Small Pox released by Tonix Pharma
- 02 Jan 2025 Pharmacokinetics data from a preclinical study in Monkey Pox released by Tonix Pharma
- 13 Nov 2024 Pharmacodynamics data from a preclinical trial in Smallpox released by Tonix Pharmaceuticals